Transparency · CHAI Applied Model Card
Advanced Cardiovascular Risk
CHAI Applied Model Card (v0.1) for the Advanced Cardiovascular Risk pattern in Zenlo Labs. This document is not CHAI-certified or CHAI-endorsed.
Header
Summary
The Advanced Cardiovascular Risk pattern evaluates Apolipoprotein B, lipoprotein(a), homocysteine, and high-sensitivity CRP — markers associated with residual cardiovascular risk beyond basic lipid panels. Deterministic rules flag elevations against pattern-specific thresholds; any qualifying abnormality fires the pattern. Claude Haiku 4.5 synthesizes physician-facing narrative on advanced lipid and inflammatory risk markers. For licensed functional-medicine physicians, this is supportive clinical decision support — it does not replace basic lipid management, family-history assessment, or coronary artery calcium scoring. Outputs highlight advanced markers warranting specialist correlation, not automated treatment decisions.
Uses & Directions
Intended use
Clinical decision support for licensed physicians reviewing advanced cardiovascular risk markers in adult panels.
Primary users
Licensed functional-medicine physicians and similarly qualified clinicians.
How to use
Review advanced markers with basic lipids, family history, blood pressure, and guideline-directed risk assessment.
Target population
Adults aged 18 and older in the United States.
Out of scope
- Direct patient use without physician oversight
- Pediatric populations
- Standalone diagnosis or statin initiation
- Replacement for coronary imaging or functional testing
Warnings
Clinical risk level
Low — supportive tool; the treating physician retains full clinical judgment and responsibility.
Known limitations
- Lp(a) is largely genetically determined; single measurements guide long-term risk, not acute changes.
- ApoB assays and reference ranges vary across laboratories.
- Homocysteine associations with CVD are modified by B-vitamin status.
Validation note
Validation pending — a Tier A NHANES validation run has not yet been completed for this pattern. Distribution, agreement, and fairness results will be published here when available.
Trust Ingredients
AI system facts
- Deterministic pattern detector (advanced_cvd_risk) plus Claude Haiku 4.5 for narrative synthesis
- Primary inputs: ApoB, Lp(a), homocysteine, and hs-CRP from structured extraction.
- Output: Pattern flag plus narrative on advanced cardiovascular marker abnormalities.
Security & compliance
- Anthropic Business Associate Agreement with zero-data-retention configuration
- HIPAA-aligned design; no patient data used for model training
Ongoing maintenance
Versioned, transparent, and reproducible via a public independent audit harness (see Resources).
Transparency
Self-funded development; no third-party sponsor for this pattern card.
Key Metrics
Usefulness / Efficacy
Zenlo’s detection approach was benchmarked across five models in a separate study; see the medRxiv preprint in Resources. No per-pattern efficacy metric is published for this pattern. Source: 5-model benchmark, medRxiv 10.64898/2026.02.13.26346284.
Fairness / Equity
Validation pending — a Tier A NHANES validation run has not yet been completed for this pattern. Distribution, agreement, and fairness results will be published here when available.
Safety / Reliability
- Supportive-only; not intended as a standalone diagnostic
- Physician authorization required before clinical use
- Deterministic detector is reproducible for inputs: APOB, LPA, HOMOCYSTEINE, HSCRP
Resources
Note: The mention or sharing of any examples, products, organizations, or individuals does not indicate any endorsement by the Coalition for Health AI (CHAI). Zenlo Labs is a clinical decision support tool intended exclusively for use by licensed healthcare providers — not a substitute for professional medical judgment, and not intended for direct patient use.
Version v0.1 · Zenlo Research